Market Overview

Why Quest Diagnostics Is Trading Higher Today


Quest Diagnostics (NYSE: DGX) shares are trading higher on Wednesday, after Morgan Stanley maintained an Overweight rating and raised its price target from $139 to $146.

Quest Diagnostics is a provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of 2,000 patient service centers, as well as multiple doctors offices and hospitals.

Quest Diagnostics shares are trading up 5% at $115.86 at time of publication on Wednesday. The stock has a 52-week high of $125 and a 52-week low of $73.02.

Latest Ratings for DGX

Oct 2020Argus ResearchUpgradesHoldBuy
Jul 2020KeyBancUpgradesSector WeightOverweight
Jul 2020Credit SuisseMaintainsNeutral

View More Analyst Ratings for DGX
View the Latest Analyst Ratings


Related Articles (DGX)

View Comments and Join the Discussion!

Posted-In: why it's movingPrice Target Analyst Ratings

Latest Ratings

PMTB of A SecuritiesMaintains18.5
IVRB of A SecuritiesMaintains3.0
EFCB of A SecuritiesMaintains15.5
NYMTB of A SecuritiesMaintains3.5
NLYB of A SecuritiesMaintains8.5
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at